 | Up a level |
Ossenkoppele, G J; Breems, D A; Stuessi, G; van Norden, Y; Bargetzi, M; Biemond, B J; A von dem Borne, P; Chalandon, Y; Cloos, J; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, J J J W; Jaspers, A; Jongen-Lavrencic, M; de Jongh, E; Klein, S K; van der Klift, M; ... (2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 34(7), pp. 1751-1759. Nature Publishing Group 10.1038/s41375-020-0725-0
Messikomer, A; Bruktawit, M; Seipel, Katja; Valk, P; Theocharides, A; Pabst, Thomas; Mckeague, M; Luedtke, N (25 May 2021). Cancer Prognosis According to Parthanatos Features (bioRxiv). Cold Spring Harbor Laboratory 10.1101/2021.05.24.445484
